Discover 1,213 paid clinical trials in Nashville, Tennessee. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Nashville offers many research opportunities for conditions such as diabetes, cardiovascular disease, and arthritis, giving participants access to innovative treatments and cutting-edge medical care. The city’s leading healthcare institutions are actively recruiting healthy volunteers for paid research studies, as well as individuals seeking trials for specific health concerns.
Filter
2
Filter results
Results: 1,213
Active & Responsive
A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors
for
Solid Tumor
Location: Nashville TN, St Louis MO, Augusta GA, Detroit MI,
Sponsor: Biohaven Therapeutics Ltd.
Sex: All
Age: 18+
Code: NCT06384807
Phase1, Phase2, Recruiting
Active & Responsive
Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease
for
Chronic Granulomatous Disease (CGD)
Location: Nashville TN, Frankfort KY, Atlanta GA, Indianapolis IN,
Sponsor: Ensoma
Sex: All
Age: 0+
Code: NCT06605378
Recruiting
Active & Responsive
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
for
Cancer, PDAC - Pancreatic Ductal Adenocarcinoma,
Location: Nashville TN, Fairfax VA, Orlando FL, Houston TX,
Sponsor: Alterome Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT06835569
Phase1, Recruiting
Active & Responsive
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
for
PIK3CA Mutation, Solid Tumor, Adult,
Location: Nashville TN, St Louis MO, Indianapolis IN, Chicago IL,
Sponsor: Relay Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT05216432
Phase1, Recruiting
Active & Responsive
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma